Patients with inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), have heightened susceptibility to several infections.1 Advances in IBD treatment options include small molecule, anti-tumor necrosis factor agents, and non-tumor necrosis factor biologics, which have greater rates of clinical remission than conventional therapy but can result in increased risk of infections.2 This evidence concerns the gene TNF and Crohn disease.